Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback